eISSN : 1309-6621
Creative Commons Lisansı
Journal of Clinical and Experimental Investigations Creative Commons Alıntı-Gayriticari 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Özet - The Positivity Ratios of HBsAg, Anti-HBs and Isolated Anti-HBc in Patients with Breast and Gynecologic Cancers Prior to Chemotherapy
Ayşe İnci, Özgür Açıkgöz, Mustafa Uygar Kalaycı, Volkan Ülker

Objective: Chemotherapy may lead to HBV re-activation. The aim of this study is to evaluate screening results for HBV infection before chemotherapy, treatment status in patients who are being followed up and planned to receive chemotherapy in our hospital.

Patients and Methods: A total of 83 patients who were admitted to Medical Oncology Outpatient Clinic of S.B.Ü. Kanuni Sultan Süleyman Research and Training Hospital between June 2015 and January 2018 and planned to receive chemotherapy were included in the study. Age, diagnoses, HBsAg, anti-HBs, anti-HBc, and HBV-DNA results of the patients were recorded through screening files.

Results: When a total of 83 patients who were planned to receive chemotherapy were analyzed with regard to cancer type; breast and ovarian cancers were found to be the most common. HBsAg positivity ratio of our patients was 3.6%, anti-HBs positivity was fund as 38.6%. Ratio of the patients whose anti-HBc was positive when HbsAg, anti-HBs negative was 7.2% (6/83) and HBV-DNA positivity was found in no of these patients.

Conclusion: In conclusion, patients should be screened for HBV infection considering risk factors like reactivation, hepatic failure, interruption of chemotherapy; we consider that conducting further studies with larger series would be important.

Key Words: HBV, chemotherapy, cancer


Cilt 9, Sayı 2 (June 2018)